Description:Fedratinib
dihydrochloride hydrate (SAR302503 or TG101348) is a novel, potent, selective,
orally bioavailable, small-molecule and ATP-competitive inhibitor of
janus kinase 2 (JAK2) with the inhibition constant IC50 of 3 nM. The
selectivity of TG101348 for JAK2 is 35- and 334-fold stronger than that
for JAK3 and JAK1 respectively. TG10348 is capable of inducing apoptosis
in HEL cells as well BaF/3 cells harboring JAK2V617 mutation and
inhibiting hematopoietic progenitor colony formation and erythroid
engraftment in samples from polycythemia vera (PV) patients.
References:Cancer Cell. 2008 Apr;13(4):311-20; Cancer Cell. 2008 Apr;13(4):321-30; Leukemia. 2010 Jul;24(7):1378-80.
Related CAS: 936091-26-8 (free base) 1374744-69-0 (TG101348 dihydrochloride hydrate)
纯度：≥98%
CAS：1374744-69-0
